V
0.283
-0.02 (-5.57%)
| Penutupan Terdahulu | 0.300 |
| Jumlah Dagangan | 385,633 |
| Harga / Jualan (P/S) | 8.00 |
| Harga / Buku (P/B) | 0.540 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -6,184.31% |
| EPS Cair (TTM) | -1.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 75.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.98% |
| Nisbah Semasa (MRQ) | 3.25 |
| Aliran Tunai Operasi (OCF TTM) | -9.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -5.03 M |
| Pulangan Atas Aset (ROA TTM) | -75.10% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | VivoSim Labs, Inc. | - | - |
AISkor Stockmoo
0.8
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 3.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.75 |
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.00% |
| % Dimiliki oleh Institusi | 6.52% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fny Investment Advisers, Llc | 30 Jun 2026 | 200 |
| Albion Financial Group /Ut | 30 Jun 2026 | 159 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LIALIN TONY SERGE | 0.290 | - | 10,000 | 2,900 |
| Jumlah Keseluruhan Kuantiti Bersih | 10,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 2,900 | |||
| Purata Pembelian Keseluruhan ($) | 0.290 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LIALIN TONY SERGE | Pegawai | 31 Aug 2026 | Beli (+) | 10,000 | 0.290 | 2,900 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |